跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 984 条关于
“Rybrevant Faspro”
全部
984
临床试验
805
药物
34
机构
6
资讯
139
3天前
Subcutaneous Amivantamab Plus Lazertinib Shows 70% 3-Year Survival in EGFR-Mutated NSCLC
3天前
PAPILLON Final Analysis: RYBREVANT Plus Chemotherapy Delivers Longest Reported Median Overall Survival in EGFR Exon 20 Insertion NSCLC
上个月
Johnson & Johnson's Oncology Pipeline Surge: Firefly Bio Acquisition, Sail Biomedicines CAR-T Deal, and OTTAVA Robotic System FDA Authorization
8个月前
Johnson & Johnson Reports 9.1% Q4 Sales Growth, Targets $100.5 Billion Revenue for 2026
3个月前
EGFR Inhibitors Market Poised for 7.9% CAGR Growth Through 2036, Driven by Next-Generation TKIs, ADCs, and Bispecific Antibodies
去年
J&J Seeks FDA and EMA Approval for Darzalex Faspro in High-Risk Smoldering Multiple Myeloma
去年
FDA Considers Darzalex Faspro for High-Risk Smoldering Multiple Myeloma
去年
Johnson & Johnson Seeks Approval for Darzalex in High-Risk Smoldering Multiple Myeloma
去年
Johnson & Johnson Seeks Approval for Darzalex Faspro in the U.S. and Darzalex in the EU for Myeloma Treatment
2年前
Rybrevant Demonstrates Promising Activity in Metastatic Colorectal Cancer
第 1 页,共 14 页
上一页
下一页